Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
| Autor: | Kageaki Watanabe, Yusuke Okuma, Makiko Yomota, Akihiko Gemma, Shoko Kawai, Yasuhiro Kato, Tatsuru Okamura, Yukio Hosomi, Kaoru Kubota, Masahiro Seike |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Multivariate analysis 03 medical and health sciences T790M 0302 clinical medicine Internal medicine medicine Osimertinib Epidermal growth factor receptor Lung cancer neoplasms biology business.industry Hazard ratio Cancer medicine.disease respiratory tract diseases Clinical trial 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Original Article business |
| Zdroj: | Journal of Thoracic Disease. 11:2350-2360 |
| ISSN: | 2077-6624 2072-1439 |
| Popis: | BACKGROUND: Osimertinib exhibits good efficacy in patients with T790M-positive non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). Compared with the clinical trials, in real-world clinical practice, osimertinib must be administered to older patients and those with poor Eastern Cooperative Oncology Group performance status (ECOG-PS). Therefore, we investigated the association between osimertinib efficacy/safety and PS score, age, and other clinical features in patients with T790M-positive NSCLC. METHODS: We reviewed all patients with T790M-positive NSCLC and acquired resistance to initial EGFR-TKIs who were administered osimertinib between March 2016 and January 2018 at the Tokyo Metropolitan Cancer and Infectious Diseases Center in Komagome Hospital, Japan. RESULTS: In total, 31 patients, including 8 young ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|